NEOG

Business Context and Reporting Period

Company: Neogen Corporation (NEOG)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended February 28, 2026
Business Overview: Neogen develops, manufactures, and markets products and services for food and animal safety. The company operates through two primary segments: Food Safety (diagnostic test kits, culture media, software) and Animal Safety (veterinary instruments, pharmaceuticals, genomics services).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 4.4% in Q3 and 3.6% year-to-date (YTD) compared to the prior year. This was primarily driven by the divestiture of the Cleaners and Disinfectants (C&D) business ($16.4M impact in Q3; $41.5M YTD) and lower sales in the Animal Safety segment due to supply chain and tariff-related issues.
• Profitability Improvement: While Q3 operating loss widened to $3.3M from a $5.4M profit in the prior year, the YTD operating loss improved significantly to $(24.7)M from $(449.8)M. The prior year's loss was heavily impacted by a $461.4M goodwill impairment charge in the Food Safety segment, which did not recur in the current period.
• Divestiture Proceeds: The company recognized a $76.4M gain on the sale of the C&D business in the prior fiscal year's Q1, contributing to YTD net income of $3.4M despite operational headwinds.
• Debt Reduction: Total debt decreased by approximately $102.4M from May 2025 to February 2026, utilizing proceeds from the C&D divestiture to repay $51.5M of the Revolving Facility, $45.0M of the Term Loan, and repurchase $3.5M of Senior Notes.

Outlook, Risks, and Unusual Items

• Genomics Divestiture: On March 2, 2026, Neogen entered a definitive agreement to sell its Genomics business to Zoetis Inc. for $160.0 million. The transaction is expected to close by the end of the first half of fiscal 2027. Assets related to this business are currently classified as "held for sale."
• Restructuring: In Q2 2026, management initiated a plan to reduce global headcount by approximately 10% and cut non-labor costs. Cumulative charges for this plan reached $6.7M as of February 28, 2026.
• Product Recall: A voluntary recall was initiated for Vet HyCoat Hyaluronate Sodium Sterile Solution due to microbial contamination. The company has accrued $0.6M for refunds but notes that potential litigation losses related to adverse events cannot yet be reasonably estimated.
• Operational Headwinds: The company faces ongoing challenges including manufacturing inefficiencies in sample collection products, duplicative costs associated with the internal transition of Petrifilm production, and supply chain disruptions exacerbated by tariffs.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of February 28, 2026, due to material weaknesses in internal control over financial reporting. A remediation plan is underway.
• Litigation: The company is facing multiple shareholder lawsuits and demands related to the integration of the 3M Food Safety business and the 2022 acquisition transaction.

Investor Verification Checklist

• Genomics Sale Closing: Verify the timeline and regulatory approval status for the $160M sale of the Genomics business to Zoetis.
• Internal Control Remediation: Monitor progress on the remediation plan for material weaknesses in internal controls, as this impacts financial reporting reliability.
• Recall Impact: Track the volume of returns and potential litigation costs associated with the Vet HyCoat product recall.
• Restructuring Execution: Confirm the realization of cost savings from the 10% headcount reduction and operational streamlining.
• Debt Covenants: Ensure continued compliance with financial covenants (funded debt to EBITDA) given the current operating loss environment.